Rajesh Narwal is a visionary biopharmaceutical executive with nearly two decades of leadership experience driving innovation across the drug development continuum — from early discovery through regulatory approval. With experience from top tier organizations, including FDA, MedImmune, AstraZeneca, and Bristol Myers Squibb and a deep portfolio of work spanning Oncology and Hematology (+other therapeutic areas), Rajesh Narwal has successfully led high-impact global programs and cross-functional teams that have advanced breakthrough therapies to patients worldwide.

Throughout his career, Rajesh Narwal has played a pivotal role in the development of both biologics and small molecule modalities, including monoclonal and multi-specific antibodies, T-cell/NK cell engagers, ADCs, novel protein degraders (CELMoD/LDD) and other modalities. He provided valuable strategic and cross-functional leadership for various key landmark therapies and investigational agents including Imfinzi, Imjudo, Enhertu, Blincyto, PD1, PD-1/PDL1 BiS, BCMA-ADCs, BCL6-LDD, HbF-CELMOD, SIRPα-mAb, CD47-CD20 BiS and others.

Known for combining scientific rigor with business acumen, Rajesh Narwal brings deep expertise across clinical development, clinical pharmacology, pharmacometrics, translational science, biostatistics, advanced analytics and regulatory strategy. His track record of delivering results in matrixed, fast-paced environments is matched by a passion for translating innovation into real-world impact for patients.